Form 4: Armata Pharmaceuticals Director Joseph M. Patti Reports Stock Option Grants

Director Joseph M. Patti reports acquisition of stock options in Armata Pharmaceuticals.

Summary

• Joseph M. Patti, a director of Armata Pharmaceuticals, reported the acquisition of stock options on March 14, 2024.
• Patti acquired 39,666 stock options that will vest upon the company's 2024 annual shareholders meeting, contingent on continuous service.
• Additionally, Patti acquired 54,343 stock options vesting in two tranches: 50% on March 14, 2025, and 50% on March 14, 2026, also subject to continuous service.
• The exercise price for both sets of options is $3.38.
• Following these transactions, Patti directly owns 94,009 stock options.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of stock option grants to a director. It suggests confidence but doesn't provide concrete performance data.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's performance, but the vesting of the options is tied to continued service, suggesting an expectation of ongoing involvement.

Industry Context

Stock option grants are a common form of compensation for directors and executives in the pharmaceutical industry, aligning their interests with those of shareholders.

Stakeholder Impact

• The granting of stock options aligns the director's interests with those of shareholders, potentially encouraging decisions that increase shareholder value.

Next Steps

• The options will vest according to the specified schedules, contingent on the director's continued service.
• The company's 2024 annual shareholders meeting will trigger the vesting of the first tranche of options.

Key Dates